Home treatment of haemophilia patients with inhibitors

Haemophilia

Volumn 17, Issue 2, 2011, Pages 173-178

  Oyesiku, J O O ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Haemophilia; Home treatment; Inhibitors; Recombinant activated factor VII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AWARENESS; BLEEDING; BLEEDING TENDENCY; BLEEDING TIME; CAREGIVER; CAREGIVER SUPPORT; CLINICAL NURSE SPECIALIST; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; DISEASE CONTROL; DRUG EFFICACY; DRUG STORAGE; EMERGENCY WARD; HEALTH EDUCATION; HEMARTHROSIS; HEMOPHILIA; HOME CARE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; JOINT INJURY; META ANALYSIS (TOPIC); PARENTAL ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SELF INJECTION; SINGLE DRUG DOSE; TREATMENT PLANNING; TREATMENT RESPONSE; VASCULAR ACCESS; VEIN PUNCTURE;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HOME NURSING; HUMANS; PATIENT EDUCATION AS TOPIC; SELF ADMINISTRATION;

EID: 79951807217     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02418.x     Document Type: Review

References (45)

1. WFH. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. Montréal, QC: WFH, 2005.
2. Scalone L, Mantovani LG, Borghetti F, Von Mackensen S, Gringeri A. Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. Haemophilia 2009; 15: 473-86.
3. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
4. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
5. Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S93-5.
6. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
7. Gringeri A, von Mackensen S, Auerswald G et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10(Suppl. 1): 26-33.
8. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
9. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
10. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
11. Brettler DB. Inhibitors in congenital haemophilia. Baillieres Clin Haematol 1996; 9: 319-29.
12. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
13. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
14. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
15. Treur M, McCracken F, Heeg B et al. Efficacy of recombinant activated factor VII (rFVIIa) vs. activated prothrombin complex concentrate (aPCC) for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009; 15: 420-36.
16. Jimenez-Yuste V, Alvarez MT, Martin-Salces M et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
17. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
18. Lusher JM. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S111-4.
19. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
20. Smejkal P, Brabec P, Matyskova M et al. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15: 743-51.
21. Salek SZ, Benson GM, Elezovic I et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2010; Apr12 [Epub ahead of print]. DOI: .
22. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
23. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
24. Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs 2008; 22: 121-36.
25. Odeyemi I, Guest J. Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK. J Med Econ 2004; 5: 119-33.
26. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.
27. Kavakli K, Yesilipek A, Antmen B et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia 2010; 16: 487-94.
28. Alliaume N, Meunier S. Self treatment training for parents in Lyon. Haemophilia 2008; 14(Suppl. 2): 121-58, 21 PO 07.
29. Mondorf W, Siegmund B, Mahnel R et al. Haemoassist - a hand-held electronic patient diary for haemophilia home care. Haemophilia 2009; 15: 464-72.
30. Pattacini C, Rivolta GF, Di Perna C, Riccardi F, Tagliaferri A. A web-based clinical record 'xl'Emofilia' for outpatients with haemophilia and allied disorders in the Region of Emilia-Romagna: features and pilot use. Haemophilia 2009; 15: 150-8.
31. Shaw D, Riley GA. The impact on parents of developments in the care of children with bleeding disorders. Haemophilia 2008; 14: 65-7.
32. Walsh M. Vein health - is there a need for ongoing education? Haemophilia 2008; 14(Suppl. 2): 121-58, 20 PO 11.
33. Choi K, Kim M, Lee K. Knowledge and behaviors regarding complication and prevention of patients with hemophilia in Korea. Journal of Thrombosis and Haemostasis 2007; 5: P-S-032.
34. Nazzaro AM, Owens S, Hoots WK, Larson KL. Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey. Am J Public Health 2006; 96: 1618-22.
35. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-32.
36. Holme PA, Glomstein A, Gronhaug S, Tjonnfjord GE. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009; 15: 727-32.
37. Petrini P, Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study. Haemophilia 2009; 15: 175-83.
38. Beheshtipour N, Cohan N, Karimi M. Home therapy and the effect of educational programmes in Iran; an alternative treatment option in developing countries. Haemophilia 2009; 15: 966-7.
39. de Jonge Harkema H, de Heusden N. Therapy compliance of Dutch children with severe haemophilia. Haemophilia 2008; 14(Suppl. 2): 121-58, 20 PO 03.
40. Kinoshita M. The importance of various educational materials that support total care for hemophiliacs. Haemophilia 2008; 14(Suppl. 2): 121-58, 21 PO 15.
41. Larkin N. Patient satisfaction following change in home treatment protocol. Haemophilia 2008; 14(Suppl. 2): 121-58, 20 PO 12.
42. Lissitchkov T, Antonov K, Georgiev G, Andreev A, Zarkova A, Goicheva M. Comprehensive haemophilia treatment center in Sofia. Haemophilia 2008; 14(Suppl. 2): 121-58, 20 PO 12.
43. Zuniga P, Morales J, Reyes L, Gonzales X, Querol F, Aznar J. Implementation of on-demand treatment protocol in adult patients with severe haemophilia by an emerging program for comprehensive care of haemophilia: preliminary results. Haemophilia 2008; 14(Suppl. 2): 121-58, 25 PO 15.
44. Vallee-Smejda S, Hahn M, Aubin N, Rosmus C. Recording practices and satisfaction of hemophiliac patients using two different data entry systems. Comput Inform Nurs 2009; 27: 372-8.
45. Berges A, Jimenez E, Espinosa L, Espinobarros L. Clinical experience of a Home Opportune Treatment Program for A and B hemophiliac patients for a leading government health care institution in a developing country (Mexico). Haemophilia 2008; 14(Suppl. 2): 121-67, 25 PO 12.